Home | Business News | Browse by Publication | C | Clinician Reviews

Xolair[R] (omalizumab): Genentech, Inc; Novartis Pharmaceuticals Corp; Tanox, Inc.

Publication: Clinician Reviews
Publication Date: 01-AUG-03
Format: Online
Delivery: Immediate Online Access
Full Article Title: Xolair[R] (omalizumab): Genentech, Inc; Novartis Pharmaceuticals Corp; Tanox, Inc.(New Drug)

Article Excerpt
An immunoglobulin E-blocker designed to reduce inflammatory response, Xolair is the first humanized therapeutic antibody indicated to treat moderate to severe persistent asthma in patients 12 and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Clinician Reviews
BreathTek[TM]: Meretek Diagnostics, Inc.(New Device), August 01, 2003
Clinical Pearls., August 01, 2003
Uncertain best treatment for de Quervain's tenosynovitis.(POEMS: Patie..., August 01, 2003
Weight loss in nonedematous CHF is a bad sign.(POEMs: Patient Oriented..., August 01, 2003
DermaDiagnosis.(A Review For The Primary Care Clinician), August 01, 2003

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.